C07K 16/2803
Against the immunoglobulin superfamily
Official title: {against the immunoglobulin superfamily}
C07K16/2803 (Against the immunoglobulin superfamily) appears on 9,337 US grants and 20,713 published applications in this corpus.
Search patents in C07K- Granted patents
- 9,337
- Published applications
- 20,713
- Assignees
- 4,294
- Inventors
- 28,417
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 5 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 4 | 0 |
| 1986 | 1 | 0 |
| 1987 | 6 | 0 |
| 1988 | 5 | 0 |
| 1989 | 7 | 0 |
| 1990 | 6 | 0 |
| 1991 | 4 | 0 |
| 1992 | 6 | 0 |
| 1993 | 15 | 0 |
| 1994 | 10 | 0 |
| 1995 | 12 | 0 |
| 1996 | 28 | 0 |
| 1997 | 54 | 0 |
| 1998 | 70 | 0 |
| 1999 | 81 | 0 |
| 2000 | 67 | 0 |
| 2001 | 62 | 28 |
| 2002 | 46 | 108 |
| 2003 | 41 | 158 |
| 2004 | 49 | 147 |
| 2005 | 38 | 177 |
| 2006 | 57 | 193 |
| 2007 | 51 | 193 |
| 2008 | 82 | 188 |
| 2009 | 112 | 260 |
| 2010 | 110 | 260 |
| 2011 | 133 | 260 |
| 2012 | 148 | 254 |
| 2013 | 167 | 367 |
| 2014 | 191 | 402 |
| 2015 | 222 | 451 |
| 2016 | 256 | 669 |
| 2017 | 326 | 823 |
| 2018 | 403 | 1042 |
| 2019 | 572 | 1408 |
| 2020 | 731 | 1681 |
| 2021 | 830 | 1960 |
| 2022 | 906 | 2120 |
| 2023 | 838 | 2012 |
| 2024 | 976 | 2220 |
| 2025 | 972 | 1869 |
| 2026 | 633 | 1463 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 16/2818Against cd28 or cd1522,807
- C07K 16/2809Against the t-cell receptor -cd3 complex1,912
- C07K 16/2827Against b7 molecules1,730
- C07K 16/2833Against mhc-molecules951
- C07K 16/283Against fc-receptors660
- C07K 16/2812Against cd4358
- C07K 16/2815Against cd8215
- C07K 16/2821Against icam molecules193
All 11 subgroupsShow fewer
Recent patents
- Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors6 Oct 2026US 12,751,956 B2Hoffmann-La Roche Inc.
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- Anti-Nectin-4 antibody, conjugate including the same, and application thereof6 Oct 2026US 12,753,230 B2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- NKG2A-targeting antibody and use thereof6 Oct 2026US 12,753,231 B2Bioheng Therapeutics Limited
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Compositions and methods for treating cancer by targeting bach18 Oct 2026US 2026/0306455 A1
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab8 Oct 2026US 2026/0306649 A1Agensys, Inc.
- Anti-trop2 antibody-drug conjugates comprising pnu-159682 derivatives8 Oct 2026US 2026/0306652 A1Merck Sharp & Dohme Corp.
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996